Mereo Biopharma Group Plc - ADR

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that on November 1, 2022, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that its American Depositary Shares (“ADSs”) failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of Nasdaq. This notification letter does not result in the immediate delisting of the Company's ADSs, and the ADSs will continue to trade, uninterrupted on the Nasdaq Global Market, under the symbol “MREO.”

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Mereo to Appoint Four New Directors to its Board of Directors

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD). The update will include commentary from and Q&A with leading pulmonary experts, further to the receipt of Fast Track Designation for alvelestat from the FDA announced on October 17, 2022.

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Reiterates Quality and Composition of Mereo's Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo's Strategy and Maximize Shareholder Value

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), today issued the following statement in response to the Company's updated operating plan: “We commend Mereo management for heeding our call for action and taking the painful but necessary step of streamlining operations in order to preserve cash.

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Designation Validates Alvelestat's Potential to Address a Serious Unmet Need

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Rubric has Rejected Mereo's Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo's Board

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), today issued an open letter to Mereo's shareholders. In its letter, Rubric details Mereo's entrenching tactics in a desperate attempt to once more thwart Rubric's effort to call a general meeting of shareholders. Rubric has delivered yet another revis

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer

Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board

This is an update on the previously written report on Mereo BioPharma Group, a London-based clinical-stage biopharma. Frustrated with the lack of engagement from the management, the activist filled a request for a special shareholder meeting aiming to replace 4 incumbent directors.

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), today issued an open letter to Mereo's shareholders. In its letter, Rubric highlighted Mereo's poor corporate governance and performance, and addressed the Company's many misleading public statements regarding Rubric's attempts to constructively engag

Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

Letter Reiterates Mereo's Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric's Assumptions

Mereo BioPharma Sends Letter to Rubric Capital Management

Gossamer Bio Inc

Nektar Therapeutics

Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Find Penny Stocks to Buy in Summer 2022

Enjoy Technology

Vallon Pharmaceuticals

Consider these tips for making a penny stocks watchlist right now The post How to Make a Penny Stocks Watchlist in July 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Make a Penny Stocks Watchlist in July 2022

Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.

Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout

Vinco Ventures

MEI Pharma

Can these penny stocks continue to make gains The post Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List

AstraZeneca plc (NASDAQ: AZN) is rumored to be eyeing take over of Mereo BioPharma Group plc (NASDAQ: MREO), according to a report in The Times. The Times' report says that "Mereo would accept $5, equating to $500 million including American depositary receipts or ADRs.

Why Mereo BioPharma Shares Are Jumping Today

AstraZeneca

AstraZeneca AZN, +0.48% AZN, +0.42% is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma MREO, +16.03% , The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialist's partners, which include Novartis NVS, +0.60% , OncXerna and Ultragenyx RARE, -1.36%.

AstraZeneca weighing bid for Mereo BioPharma: report

Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE)

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

Clean Energy Fuels

HUYA Inc - ADR

IMAC Holdings Inc

23andMe

Top Wall Street Investors Own These 5 Penny Stocks. Are They A Buy Now?

Best Penny Stocks To Buy? Einhorn, Lynch, Cohen & Dalio Own These 5

Allena Pharmaceuticals

Imperial Petroleum

Here's what you need to know about trading penny stocks on May 9th The post What to Know About Trading Penny Stocks on Monday, May 9th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Trading Penny Stocks on Monday, May 9th

Mereo BioPharma Group plc (NASDAQ: MREO) has announced topline efficacy and safety results from ASTRAEUS Phase 2 study of alvelestat (MPH-966) in severe alpha-1 antitrypsin deficiency-(AATD) associated emphysema. Emphysema is a lung disease caused by damage to the small air sacs in.

Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease

Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET

News for Mereo Biopharma Group Plc - ADR Stock (MREO)